Photo Credit: Debbie Hill/UPI
Pfizer expects to sell $54 billion worth of COVID-19 shots, treatment pills in 2022
The company reported its 2022 forecast in its quarterly earnings report, which showed that Pfizer made almost $24 billion in revenue in the final quarter of 2021. About half of that came from sales of its COVID-19 vaccine and $76 million from sales of its antiviral treatment Paxlovid, which was the first COVID-19 treatment pill authorized in the United States.
